Zobrazeno 1 - 10
of 181
pro vyhledávání: '"AcademicSubjects/MED00295"'
Autor:
Duaa W Al-Sadeq, Farah M Shurrab, Ahmed Ismail, Fathima Humaira Amanullah, Swapna Thomas, Nader Aldewik, Hadi M Yassine, Hanan F Abdul Rahim, Laith Abu-Raddad, Gheyath K Nasrallah
Publikováno v:
Journal of Travel Medicine
Background Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is known about the difference in antibody responses induced by these two mRNA vaccines in naïve a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2002ac7e49ddf2f353ea9416882a6a
https://hdl.handle.net/10576/25665
https://hdl.handle.net/10576/25665
Publikováno v:
Journal of Travel Medicine, 28(8). OXFORD UNIV PRESS INC
Journal of Travel Medicine
Journal of Travel Medicine
Background In 2013, the World Health Organization (WHO) revised their position on yellow fever vaccination, in which revaccination every 10 years was no longer required, and that a single-dose provided life-long protection. However, research data on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8f58e15f5840f1f7dbc8cd1878417a
https://hdl.handle.net/1887/3303601
https://hdl.handle.net/1887/3303601
Autor:
Gururaj Rao Deshpande, Prudhvi Lal Bhukya, Pragya D Yadav, Asha Salunke, Chetan Patil, Bipin N Tilekar, Aparna Rakhe, Rashi Srivastava, Yogesh K Gurav, Varsha Potdar, Priya Abraham, Gajanan N Sapkal
Publikováno v:
Journal of Travel Medicine
The Delta variant leads to the resurgence of the second wave in India. A 1.51-fold increase in neutralizing antibody response was observed in the second wave compared with first wave, indicating the second wave dominated by the Delta elicited a robus
Autor:
Binaya Sapkota, Bhuvan Saud, Ranish Shrestha, Dhurgham Al-Fahad, Ranjit Sah, Sunil Shrestha, Alfonso J Rodriguez-Morales
Publikováno v:
Journal of Travel Medicine
Background/ObjectiveHeterologous prime–boost doses of COVID-19 vaccines (‘mix-and-match’ approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines fo
Autor:
Turbett, Instructor Sarah E, Becker, Doctoral Student Margaret, Belford, Medical Technologist Barbara, Kelly, Research Technologist Meagan, Desrosiers, Medical Technologist Lisa, Oliver, Research Nurse Elizabeth, Branda, Associate Professor John A, Walters, Epidemiologist Maroya, Walker, Epidemiologist Allison Taylor, LaRocque, Associate Professor Regina, Ryan, Professor Edward T
Publikováno v:
Journal of Travel Medicine
We establish the feasibility of evaluating US international travellers for Candida auris acquisition using a culture-based screening protocol. Candida auris was not identified in any of the travellers in this small cohort; further study is needed to
No further delays in offering booster doses in countries experiencing a major resurgence of COVID-19
Publikováno v:
Journal of Travel Medicine
Covid booster shots should be proposed and recommended to all fully vaccinated individuals, considering antibody levels are waning over time and that the risk of being infected typically reappears after 6 months.
Autor:
Annelies Wilder-Smith
Publikováno v:
Journal of Travel Medicine
Despite coronavirus disease 2019-related disruptions in controlling dengue, efforts need to be maintained to prevent vector-borne diseases during this pandemic. Although travel restrictions brought a global halt to mobility and therefore also a subst
Autor:
Thayane Santos Siqueira, Edyankya Karolyne Gomes de Souza, Paulo Ricardo Martins-Filho, José Rodrigo Santos Silva, Ricardo Queiroz Gurgel, Luis Eduardo Cuevas, Victor Santana Santos
Publikováno v:
Journal of Travel Medicine
Background Monitoring the characteristics and associated factors for death among pregnant and postpartum women with coronavirus disease 19 (COVID-19) is necessary. We investigated the clinical characteristics and risk factors associated with maternal
Autor:
Dimpal A Nyayanit, Kamran Zaman, Samiran Panda, Rajni Kant, Sandeep Chaowdhary, Rima R Sahay, Himanshu Kaushal, Balram Bhargava, Nivedita Gupta, Gaurav Dwivedi, Gajanan Sapkal, Pragya D Yadav, Priya Abraham, Sanjay Kumar, Rajeev Singh, Gururaj Deshpande
Publikováno v:
Journal of Travel Medicine
The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion B
Autor:
Joel A. Malek, Hiam Chemaitelly, Gheyath K. Nasrallah, Einas Al Kuwari, Anvar Hassan Kaleeckal, Hadi M. Yassine, Hamad Eid Al Romaihi, Abdullatif Al Khal, Hanan F. Abdul Rahim, Riyazuddin Mohammad Shaik, Patrick Tang, Zaina Al Kanaani, Roberto Bertollini, Laith J. Abu-Raddad, Fatiha M. Benslimane, Mohamed Ghaith Al Kuwari, Adeel A. Butt, Andrew Jeremijenko, Ali Nizar Latif, Hebah A. Al Khatib, Mohamed H. Al-Thani, Peter Coyle, Houssein H. Ayoub
Publikováno v:
Abu-Raddad, L J, Chemaitelly, H, Yassine, H M, Benslimane, F M, Al Khatib, H A, Tang, P, Malek, J A, Coyle, P, Ayoub, H H, Al Kanaani, Z, Al Kuwari, E, Jeremijenko, A, Kaleeckal, A H, Latif, A N, Shaik, R M, Abdul Rahim, H F, Nasrallah, G K, Al Kuwari, M G, Al Romaihi, H E, Al-Thani, M H, Al Khal, A, Butt, A A & Bertollini, R 2021, ' Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses ', Journal of Travel Medicine, vol. 28, no. 7 . https://doi.org/10.1093/jtm/taab083
Journal of Travel Medicine
Journal of Travel Medicine
Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week-by-week after the first dose. 75% of protection against infection and disease is reached 15-21 daysafter the first dose. Protection increased most ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8fb9c9233378e6cf83f4f8b8018a61
https://pure.qub.ac.uk/en/publications/pfizerbiontech-mrna-bnt162b2-covid19-vaccine-protection-against-variants-of-concern-after-one-versus-two-doses(07dafac5-ed82-43b5-ada0-1881fd589d98).html
https://pure.qub.ac.uk/en/publications/pfizerbiontech-mrna-bnt162b2-covid19-vaccine-protection-against-variants-of-concern-after-one-versus-two-doses(07dafac5-ed82-43b5-ada0-1881fd589d98).html